ArticleFrontiers in nutrition2026
Immunomodulatory effects of short-chain fatty acids and immune-supporting nutrients on slice cultures of head and neck tumors.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Head and neck squamous cell carcinoma (HNSCC) has a highly immunosuppressive tumor microenvironment (TME), which limits the effectiveness of conventional and immunotherapies. Metabolites derived from the gut microbiota, such as short-chain fatty acids (SCFAs), and targeted nutritional interventions, including immunonutrition (IN), have been proposed as ways of influencing tumor immunity and cell viability. However, the effects of these factors on the complex TME of HNSCC remain incompletely understood. Patient-derived organotypic slice cultures (SC) therefore provide a clinically relevant model to study these interactions. Methods: SC were generated from tumors of nine HNSCC patients and cultured under four conditions: control; SCFAs; IN (glutamine, alanine, and omega-3 fatty acids); and SCFAs combined with IN, for 4 days. Apoptotic activity was assessed via cleaved caspase-3 (CC3), and cytotoxic activity via Granzyme B (GrB) staining. Inflammatory markers (IL-1β, IL-6, TNFα and IFNγ) were quantified in cultured and treated tissue, as well as in the tissue's supernatant. Quantitative immunohistochemistry (IHC) - based image analysis and dot blot assays were combined with statistical evaluation of patient- and treatment-specific effects. Results: Treatments with IN alone or in combination with SCFAs significantly reduced CC3 intensity, indicating decreased apoptosis. However, SCFA treatment alone increased CC3 intensity in SC of certain patients. GrB IHC intensity remained largely stable, with patient-specific differences driving the observed variability. Among the cytokines analyzed in the SC supernatants, TNFα and IL-1β were selectively modulated by IN and combined treatment, while IL-6 and IFN- Conclusion: SCFAs and IN exert modest but selective effects on apoptosis and inflammatory pathways in HNSCC, whereas cytotoxic activity remains stable. These results support the potential of tailoring metabolic and nutritional interventions to individual patients to modulate the tumor immune microenvironment, and provide a rationale for integrating SCFAs and IN with immunotherapeutic strategies in HNSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.